Is Egrifta (Tesamorelin) Legal in Ohio? How to Access It Legally

HealthRX.com

Egrifta is a federally approved prescription drug

Print or save as PDF

Key numbers

  • 1.28 mgEgrifta WR daily dose; the label says it is not substitutable with Egrifta SVSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 4.1 percentage pointsLiver fat reduction vs placebo over 12 months in a 2019 trial of 61 people with HIV and fatty liverSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 7, 2026
  • 25%Injection-site reactions on tesamorelin over the first 26 weeks, versus 14% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 5%Patients on tesamorelin who developed HbA1c of 6.5% or higher, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • FDA status / Prescription drug under application 022505; first approved November 10, 2010 [1]
  • Current labels / Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [2][4]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy only [2]
  • Dose / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; the Egrifta WR label says the two are not substitutable [2][4]
  • Boxed warning / None in either current label [2][4]
  • Compounding / Not on FDA's significant-safety-risk list; FDA has made no category-based statement [5][6][7]
  • Sport / Named in WADA S2.2.4; prohibited at all times [8][9]

What is Egrifta's federal status?

FDA lists Egrifta under application 022505 as a prescription product first approved November 10, 2010; the former new drug application was later deemed a biologic license application [1]. Egrifta SV is a 2 mg per vial formulation dosed at 1.4 mg subcutaneously into the abdomen once daily. Egrifta WR is an 11.6 mg per vial formulation dosed at 1.28 mg once daily, and its label states the two are not substitutable [2][4].

Tesamorelin is a synthetic analog of human growth hormone-releasing factor, a peptide rather than growth hormone. It stimulates GRF receptors on pituitary somatotroph cells, which leads to growth hormone release and raises IGF-1 and IGFBP-3 [2].

Can a prescriber use it off-label?

FDA's patient guidance says that once a drug is approved, health care providers generally may prescribe it for an unapproved use when they judge it medically appropriate, and that FDA has not determined the drug is safe and effective for that use [3].

Egrifta is not approved for weight loss management, and its label describes a weight-neutral effect [2]. The trials behind the approval enrolled HIV-infected adults with excess abdominal fat on stable antiretroviral therapy [2]. A 2019 trial that enrolled 61 people with HIV and fatty liver found liver fat fell by an absolute 4.1 percentage points more than placebo over 12 months [10]. The approved use is reducing excess abdominal fat in HIV-infected adults with lipodystrophy, and FDA has not approved tesamorelin for fatty liver [2].

Questions worth asking

Choose the questions you want to keep

What does the label say to watch for?

Contraindications are disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][4].

The Egrifta SV label warns about cancer history, elevated IGF-1 and glucose intolerance [2]. Among patients treated 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS [2]. HbA1c of 6.5% or higher developed in 5% on tesamorelin versus 1% on placebo, hazard ratio 3.3 (95% CI 1.4 to 9.6) [2]. Injection-site reactions occurred in 25% versus 14% over the first 26 weeks, and hypersensitivity reactions in 4% [2].

Can tesamorelin be compounded?

Tesamorelin is not on FDA's page of bulk substances that may present significant safety risks when compounded. It appears in no category of FDA's list for state-licensed pharmacies and physicians or of its list for outsourcing facilities, so FDA has made no category-based statement about compounding it [5][6][7]. Compounded drugs are not FDA-approved [11].

Is Egrifta (tesamorelin) a prescription drug?
Yes. FDA lists Egrifta under application 022505 as a prescription product first approved November 10, 2010. [1]
What is Egrifta approved to treat?
Only the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. The label says it is not indicated for weight loss management because its effect on weight is neutral. [2]
What dose do the labels give?
Egrifta SV is 1.4 mg injected subcutaneously into the abdomen once daily; Egrifta WR is 1.28 mg once daily. The Egrifta WR label states the two are not substitutable. [2][4]
Show all 11 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. Understanding Unapproved Use of Approved Drugs "Off Label" | FDA.
  4. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  6. U.S. Food and Drug Administration.
  7. U.S. Food and Drug Administration.
  8. World Anti-Doping Agency.
  9. World Anti-Doping Agency.
  10. Stanley TL, Fourman LT, Feldpausch MN, Purdy J, Zheng I, Pan CS, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821-e830.
  11. Human Drug Compounding Laws | FDA.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Ohio? How to Access It Legally